• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Theravance

Theravance

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. The Benefits of Diversifying the Funding of a Gold Position

    Theravance THRX reported second-quarter earnings that matched our expectations, and we are keeping our fair value estimate at $29 per share. The company continues to make progress in each of its programs, namely the addition of a second Phase IIb compound in the Beyond Advair trials and completion ...

  2. China COPD Drugs Market Growth of 15.56% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: AstraZeneca, GSK, Novartis - Research and Markets

    China COPD Drugs Market Growth of 15.56% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2016-2020 - Key Vendors: AstraZeneca, GSK, Novartis - Research and Markets

  3. An ETF for This Lagging Sector

    Biotech companies' returns have diverged from the broader market in recent weeks amid concerns over greater regulation and price discounting.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.